DongA-ST said Tuesday that it has finished construction of “PT Combiphar Donga Indonesia,” a biopharmaceutical production plant, also invested by Indonesia's partner company Combiphar.
|This is the plant dedicated by DongA-ST in Jababeka Industrial Complex, Indonesia, recently.|
The $15 million factory, located in Jababeka Industrial Complex, Indonesia, can produce 4.7 million free-field injections annually. The company has also equipped the plant with waste treatment and hazardous material treatment facilities.
The two companies expect that the plant will become fully operational in 2020 after validation of various equipment and production processes, while also receiving local GMP certification.
After the plant starts its operation, DongA-ST will export raw biopharmaceutical materials for its products such as Eporon, an anemia treatment for chronic renal failure patients, and Leucostim, a neutropenia treatment, to the plant. Combiphar will be in charge of production and local marketing.
Before the full-scale operation of the plant, Dong-A ST also plans to export Eporon and Leucostim through Combiphar to secure product recognition in the Indonesian market.
“With the completion of the local production plant, Dong-A ST has secured a bridgehead in the Indonesian market, while Combiphar has secured a growth engine to become a leading Indonesian pharmaceutical company,” a Dong-A ST official said. “The company will do its best to successfully market our drug in the Indonesian market by continuing to cooperate with Combiphar.”
<© Korea Biomedical Review, All rights reserved.>